Anti-nectin-4 antibodies and uses thereof

Humanized monoclonal antibodies with enhanced specificity for tumor Nectin-4 reduce skin toxicity and improve cancer treatment efficacy by targeting Nectin-4-expressing tumors with reduced side effects.

JP7579990B2Active Publication Date: 2024-11-08EMERGENCE THERAPEUTICS GMBH +4
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023561035
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-11-19
Filing Date
2022-03-31
Publication Date
2024-11-08
Estimated Expiration
2042-03-31

AI Technical Summary

Technical Problem

Current cancer treatments targeting Nectin-4 often result in significant skin toxicity due to non-specific binding to both tumor and normal keratinocytes, limiting their therapeutic efficacy and safety.

Method used

Development of humanized monoclonal antibodies, such as 15A7.5 mAb, with enhanced specificity for tumor-expressed Nectin-4, reducing binding to normal keratinocytes and conjugated with cytotoxic agents like exatecan, to achieve targeted cancer therapy with reduced skin toxicity.

Benefits of technology

The antibodies demonstrate higher affinity and selectivity for tumor Nectin-4, leading to rapid and long-lasting tumor regression with lower skin toxicity, as shown in xenograft mouse models, and improved therapeutic index.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579990000001
    Figure 0007579990000001
  • Figure 0007579990000002
    Figure 0007579990000002
  • Figure 0007579990000003
    Figure 0007579990000003
Patent Text Reader

Abstract

The present invention relates to an antibody having specificity for Nectin-4 and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] 2. Background of the Invention The present invention relates to an antibody having specificity for Nectin-4 and uses thereof. [Background technology]

[0002] Nectins are adhesion molecules that help organize epithelial and endothelial junctions and serve as receptors for the entry of herpes simplex, measles and polioviruses.

[0003] Nectins belong to the immunoglobulin superfamily and are homologues of the poliovirus receptor (PVR / CD155), and therefore have also been called poliovirus receptor-binding proteins (PRRs). To date, five members have been described: PVR / CD155, nectin-1 / PRR1 / CD111, nectin-2 / PRR2 / CD112, nectin-3 / PRR3, and nectin-4 / PRR4 (1, 10–13). Their extracellular domains are composed of three immunoglobulin-like (Ig)-type V, C, and C domains that share between 30% and 55% identity in their amino acid sequences.

[0004] Expression of nectin / PRR molecules is generally widespread in tissues including hematopoietic, neuronal, endothelial and epithelial cells, with the exception of nectin-3 and -4, which show a more restricted expression profile.

[0005] Nectin-4 is a particularly interesting target. It is expressed during fetal development, but its expression is reduced and highly restricted in adult tissues compared to that of other members of the nectin family. Nectin-4 is a tumor-associated antigen in 83% of bladder cancers, 78% of breast cancers (mainly triple negative and ERBB2+), 71% of pancreatic cancers, 55% of lung cancers, 57% of ovarian cancers, 59% of head and neck cancers, and 55% of esophageal cancers.

[0006] Expression of Nectin-4 in these pathologies is associated with poor prognosis, possibly as a result of its ability to confer a higher capacity for migration, proliferation and formation of metastases to tumor cells in vitro. In normal tissues, Nectin-4 is only detected in the skin, salivary glands, bladder and esophagus. The recent approval by health authorities of Enfortumab Vedotin for the second-line treatment of advanced urothelial carcinoma has completed the validation of Nectin-4 as a target for the treatment of cancer. Summary of the Invention

[0007] Detailed Description of the Invention The present invention relates to an antibody having specificity for Nectin-4, an antigen-binding fragment thereof, and uses thereof.

[0008] In particular, the present invention provides humanized antibodies derived from the monoclonal anti-Nectin-4 antibody 15A7.5 mAb.

[0009] The present inventors provide for the first time an antibody, namely 15A7.5 mAb, which specifically binds with higher affinity to tumor-expressed Nectin-4 compared to Nectin-4 expressed by human differentiated keratinocytes, as well as antibodies derived therefrom. In vitro, this selectivity provides mAb 15A7.5 with lower binding affinity, internalization and cytotoxic activity to keratinocytes compared to tumor cells and with reference to the activity of HA22 mAb (Enfortumab) in the same assay.

[0010] In vivo, this low binding capacity to keratinocytes confers a longer half-life to mAb 15A7.5 due to a lower absorption rate in the skin.

[0011] In a xenograft mouse model, treatment of established tumors with a single intravenous dose of 4 mg / kg of the mAb conjugated to exatecan led to rapid and durable regression.

[0012] More specifically, the inventors demonstrate that in such a configuration, 15A7.5 is more efficient than a surrogate of enfortumab vedotin, i.e., an enfortumab vedotin product manufactured using non-GMP methods by a third party that is indistinguishable from commercially available enfortumab vedotin.

[0013] Thus, the antibody 15A7.5, and in particular the humanized variants derived therefrom, represent a new way to improve the therapeutic index of Nectin-4 positive cancer treatment, i.e. through lower associated skin toxicity and higher anti-tumor selectivity and efficacy.

[0014] Thus, a first aspect of the present invention relates to a monoclonal antibody or antigen-binding fragment thereof that binds to Nectin-4, characterized by a VH region and optionally a VL region that contain three CDRs, termed CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3, respectively, that define the binding specificity of the antibody or antigen-binding antibody fragment. Binding to human Nectin-4 is preferred.

[0015] The antibodies of the present invention are monoclonal antibodies (mAbs) or monoclonal antibody fragments characterized by a particular amino acid sequence. Unless otherwise indicated, the term "monoclonal" refers to antibodies or antibody fragments of a single species, i.e., of a single amino acid composition.

[0016] The antigen-binding site of an antibody of the present invention comprises a heavy chain variable domain / region (VH) and / or an antibody light chain variable domain / region (VL), or a VH / VL pair. By variable domain / region is meant each of the light and heavy chain pairs that are directly involved in binding the antibody to the antigen. The variable domain of the heavy chain is abbreviated as "VH" and the variable domain of the light chain is abbreviated as "VL".

[0017] The term "antigen-binding site" refers to the region(s) of an antibody molecule derived from an antibody to which a ligand (e.g., an antigen, i.e., Nectin-4, or an antigenic fragment thereof) actually binds.

[0018] The antigen-binding site of the antibody according to the invention may contain six complementarity determining regions (CDRs) that contribute to different extents to the affinity of the binding site for the antigen. There are three heavy chain variable domain CDRs (CDR-H1, CDR-H2 and CDR-H3) and three light chain variable domain CDRs (CDR-L1, CDR-L2 and CDR-L3). Also included within the scope of the invention are functional antigen-binding sites that are composed of fewer CDRs (i.e., the binding specificity is determined by three, four or five CDRs). For example, less than the complete set of six CDRs may be sufficient for binding. In some cases, a VH domain or a VL domain will be sufficient.

[0019] According to the present invention, the VH region or its CDRs alone may constitute a complete antigen-binding site.In certain embodiments, the antibody comprises only the VH region or its CDRs as defined herein.In other embodiments, the antibody comprises the VH region or its CDRs as defined herein together with the VL region or its CDRs, in particular the VL region or its CDRs as defined herein.

[0020] The position of the CDRs within the VH or VL regions may be defined according to Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991) or the IMGT numbering system, both of which are known to those skilled in the art. The IMGT numbering has been defined to compare variable domains, whatever the antigen receptor, chain type, or species (Lefranc M.-P., "Unique database numbering system for immunogenetic analysis" Immunology Today, 18, 509 (1997); Lefranc M.-P., "The IMGT unique numbering for Immunoglobulins, T cell receptors and Ig-like domains" The Immunologist, 7, 132-136 (1999)).

[0021] A further aspect of the present invention is (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 has an amino acid sequence according to SEQ ID NO: 1 or 7, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (ii) the CDR-H2 has an amino acid sequence according to SEQ ID NO: 2 or 8, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (iii) the CDR-H3 has an amino acid sequence according to SEQ ID NO: 3 or 9, or a substitution, in particular a conservative substitution of one or two amino acids, and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 4 or 10, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (ii) the CDR-L2 has an amino acid sequence according to SEQ ID NO: 5 or 11, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (iii) the CDR-L3 has an amino acid sequence according to SEQ ID NO: 6 or 12, or a substitution, particularly an amino acid sequence containing a conservative substitution of one or two amino acids, The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof that binds to Nectin-4, comprising:

[0022] The specific amino acid sequences represented by SEQ ID NOs used herein are provided in the attached sequence listing. SEQ ID NOs: 1-6 define the six CDR sequences of the parent antibody of the invention according to the IMGT numbering system. SEQ ID NOs: 7-12 define the six CDR sequences of the parent antibody of the invention according to Kabat. Unless otherwise stated, the Kabat system is used herein.

[0023] According to the present invention, substitution of one or two amino acids in these CDR sequences is possible.In certain embodiments, conservative amino acid substitutions, i.e. substitution of an amino acid with another amino acid having similar biochemical properties, such as substitution of an aliphatic amino acid, such as Gly, Ala, Val, Leu or Ile, for another aliphatic amino acid, substitution of a basic amino acid, such as His, Lys or Arg, substitution of an acidic amino acid or its amide, such as Asp, Glu, Asn or Gln, for another acidic amino acid or its amide, substitution of an aromatic amino acid, such as Phe, Tyr or Trp, for another aromatic amino acid, or substitution of a hydroxyl or sulfur-containing amino acid, such as Ser, Thr, Met or Cys, for another hydroxyl or sulfur-containing amino acid.

[0024] "Antigen-binding fragment" of an antibody refers to a molecule that comprises a portion of an intact antibody that binds to the antigen that the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabody; linear antibody; single-chain antibody molecule (e.g., scFv); and multispecific antibodies formed from antibody fragments. The term also includes fusion proteins, such as fusion proteins with non-immunoglobulin peptides or polypeptides, and conjugates with non-proteinaceous structures, such as labels or toxins. The terms "antigen-binding fragment of an antibody", "antigen-binding fragment thereof", "fragment of an antibody" or "fragment thereof" may be used interchangeably herein.

[0025] The antibody or antigen-binding fragment of the present invention may be monovalent or multivalent, i.e., it may contain a single antigen-binding site or multiple antigen-binding sites. For example, a Fab fragment has a single antigen-binding site, an antibody of the IgG class or an Fv fragment or scFv fragment has two antigen-binding sites, and an antibody of the IgM class has five antigen-binding sites. The term "antibody" also includes heterospecific antibodies with different antigen-binding sites, such as heterobispecific antibodies, in particular antibodies directed to two different epitopes on an antigen. As used herein, an "epitope" is the region of an antigen to which an antibody binds. The term "epitope" includes any polypeptide determinant that can specifically bind to an antibody.

[0026] According to a further preferred embodiment, the antibody or antigen-binding fragment thereof is numbered according to the IMGT numbering system: (i) a VH region comprising a CDR-H1 of SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 2, and a CDR-H3 of SEQ ID NO: 3, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 4, CDR-L2 of SEQ ID NO: 5, and CDR-L3 of SEQ ID NO: 6 Includes.

[0027] In another preferred embodiment, the antibody or antigen-binding fragment thereof is (i) a VH region comprising CDR-H1 of SEQ ID NO: 7, CDR-H2 of SEQ ID NO: 8, and CDR-H3 of SEQ ID NO: 9; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 10, CDR-L2 of SEQ ID NO: 11, and CDR-L3 of SEQ ID NO: 12 Includes.

[0028] More specifically, the antibody or antigen-binding fragment thereof comprises: (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 13, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto over the entire length of said sequence; and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 14, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto over the entire length of said sequence. may include.

[0029] "Percent (%) amino acid sequence identity" with respect to a peptide or polypeptide sequence is defined as the percentage of amino acid residues in a particular peptide or polypeptide sequence that are identical to the amino acid residues in that sequence after aligning the candidate sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be accomplished in a variety of ways that are within the skill of one of ordinary skill in the art, for example, using publicly available computer software such as BLAST.

[0030] The antibody of the present invention may be a chimeric antibody, a multispecific antibody, in particular a bispecific antibody, a human antibody, a humanized antibody or an antigen-binding fragment thereof.

[0031] According to the present invention, a "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular origin or species, while the remainder of the heavy and / or light chain is derived from a different origin or species.

[0032] A "multispecific antibody" binds to two or more different epitopes. The epitopes can be on the same or different antigens. A preferred example of a multispecific antibody is a "bispecific antibody" that binds to two different epitopes.

[0033] In a preferred embodiment, the antibody of the present invention is a humanized antibody.

[0034] The term "humanized antibody" or "humanized version of an antibody" refers to an antibody in which both the heavy and light chains have been humanized as a result of antibody engineering. A humanized chain is typically a chain in which the amino acid sequence of the V region has been altered so that it is closer in homology to the human germline sequence than the germline sequence of the original species when analyzed as a whole. For example, mouse CDRs can be grafted into the framework region of a human antibody to prepare a "humanized antibody". See, for example, Riechmann, L., et al., Nature 332 (1988) 323-327; and Neuberger, MS, et al., Nature 314 (1985) 268-270. Other forms of humanized antibodies encompassed by the present invention are those in which the constant region has been further modified or altered from that of the original antibody to produce the properties according to the present invention. The assessment of humanization is based on the resulting amino acid sequence, not on the methodology itself.

[0035] Another preferred embodiment relates to human antibodies.

[0036] The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies are well known in the state of the art (van Dijk, MA, and van de Winkel, JG, Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) that, upon immunization, can produce a full repertoire or a selection of human antibodies without endogenous immunoglobulin production.

[0037] The antibody of the present invention may be of any suitable class. The term "class" refers to the type of constant domain or constant region possessed by its heavy chain. As used herein, "constant domain" or "constant region" refers to the totality of domains of an antibody other than the variable region. The constant region is not directly involved in binding the antigen, but exhibits various effector functions. The antibody may be of any of the five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, or any subclass (isotype) thereof, e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the various classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. According to the present invention, antibodies of class IgG, IgA, or IgM, or fragments thereof, are particularly preferred.

[0038] According to a preferred embodiment, the antibody of the invention is selected from the class IgG, such as the subclasses IgG1, IgG2, IgG3 or (of) IgG4, the class IgM, the class IgA or an antigen-binding fragment thereof.

[0039] In a particular embodiment, the humanized or human antibody of the invention is defined by a combination of at least three, and preferably six, complementarity determining regions (CDRs), i.e. (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 is an amino acid sequence according to SEQ ID NO: 21, 35, 49 or 63, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (ii) the CDR-H2 has an amino acid sequence according to SEQ ID NO: 22, 36, 50 or 64 or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (iii) the CDR-H3 has an amino acid sequence according to SEQ ID NO: 23, 37, 51 or 65, or substitutions, in particular conservative substitutions of one or two amino acids, (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 24, 38, 52 or 66, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (ii) the CDR-L2 is an amino acid sequence according to SEQ ID NO: 25, 39, 53 or 67, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (iii) the CDR-L3 is an amino acid sequence according to SEQ ID NO: 26, 40, 54 or 68, or a substitution, particularly an amino acid sequence containing a conservative substitution of one or two amino acids, The present invention relates to an antibody or antigen-binding fragment thereof comprising:

[0040] Particular humanized or human antibodies according to the invention include (a)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (b)(i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (c)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54; or (d)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67 and CDR-L3 of SEQ ID NO: 68; or (e)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39 and CDR-L3 of SEQ ID NO: 40; or (f)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53 and CDR-L3 of SEQ ID NO: 54; or (g)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67 and CDR-L3 of SEQ ID NO: 68; or (h)(i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25 and CDR-L3 of SEQ ID NO: 26; or (j) (i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53 and CDR-L3 of SEQ ID NO: 54; or (k) (i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67 and CDR-L3 of SEQ ID NO: 68; or (l)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25 and CDR-L3 of SEQ ID NO: 26; or (m)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39 and CDR-L3 of SEQ ID NO: 40; or (n) (i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67 and CDR-L3 of SEQ ID NO: 68; or (o)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25 and CDR-L3 of SEQ ID NO: 26; or (p)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39 and CDR-L3 of SEQ ID NO: 40; or (q)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53 and CDR-L3 of SEQ ID NO: 54 may include.

[0041] Particularly preferred are the humanized antibodies (a), (b), (c), (d), (j), (k), (n) and (q) as defined above.

[0042] Of course, humanized or human antibodies according to the invention can also be defined by their VH and / or VL regions.

[0043] Such antibodies are (i) a VH region comprising an amino acid sequence selected from SEQ ID NO: 27, 41, 55, or 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence selected from SEQ ID NOs: 28, 42, 56, 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. may include.

[0044] Particular humanized or human antibodies according to the invention may be defined by their VH and / or VL regions, where such antibodies comprise: (a)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (b)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (c)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (d)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (e)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (f)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (g)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (h)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (j)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (k)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (l)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (n)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; (o)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (p)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (q)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. Includes.

[0045] Particularly preferred are the humanized antibodies (a), (b), (c), (d), (j), (k), (n) and (q) as defined above.

[0046] According to a particularly preferred embodiment, the antibodies and antigen-binding fragments thereof of the present invention bind with higher affinity to tumor-expressed Nectin-4 compared to Nectin-4 expressed by human differentiated keratinocytes. Such specific binding allows, inter alia, fewer side effects during therapy based on the antibodies of the present invention, in particular reduced skin toxicity.

[0047] The terms "binding" and "specific binding" as used herein refer to the binding of the antibody of the present invention or its fragment to the epitope of Nectin-4 antigen. The measure of the binding strength of the antibody is called affinity. Methods for determining such binding and / or affinity using in vitro assays are known to those skilled in the art. According to the present invention, detection by flow cytometry, immunohistochemistry and / or fluorescence are described herein and are particularly preferred.

[0048] The affinity of binding of an antibody to an antigen is measured using the terms Ka (rate constant for the association of the antibody from the antibody / antigen complex), KD (dissociation constant), and K dis It is defined by (kD / ka).

[0049] The antibodies and antigen-binding fragments thereof according to the invention preferably exhibit a dissociation constant KD of at least 40, preferably at least 45, more preferably at least 50 and most preferably at least 55 (nM).

[0050] A particularly preferred embodiment of the present invention comprises (i) a VH region comprising a CDR-H1 of SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 2, and a CDR-H3 of SEQ ID NO: 3, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 4, CDR-L2 of SEQ ID NO: 5, and CDR-L3 of SEQ ID NO: 6 A humanized antibody and antigen-binding fragment thereof comprising: The present invention relates to antibodies and antigen-binding fragments thereof that bind with higher affinity to Nectin-4 expressed by tumors compared to Nectin-4 expressed by human differentiated keratinocytes.

[0051] A further aspect of the present invention relates to the monoclonal anti-Nectin-4 antibodies 9A2.7, 3A1.4, and 8F06 described herein and antigen-binding fragments thereof. Humanized variants of these antibodies are preferred.

[0052] That is, the present invention also provides (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 is an amino acid sequence according to SEQ ID NO: 79, 87 or 95, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (ii) the CDR-H2 has an amino acid sequence according to SEQ ID NO: 80, 88 or 96, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (iii) the CDR-H3 has an amino acid sequence according to SEQ ID NO: 81, 89 or 97, or substitutions, in particular conservative substitutions of one or two amino acids, (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 83, 91 or 99, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (ii) the CDR-L2 is an amino acid sequence according to SEQ ID NO: 84, 92 or 100, or an amino acid sequence containing substitutions, in particular conservative substitutions of one or two amino acids, (iii) the CDR-L3 is an amino acid sequence according to SEQ ID NO: 85, 93 or 101, or a substitution, particularly an amino acid sequence containing a conservative substitution of one or two amino acids, The present invention provides a monoclonal antibody or an antigen-binding fragment thereof that binds to Nectin-4, comprising:

[0053] One embodiment comprises: (i) a VH region comprising CDR-H1 of SEQ ID NO: 79, CDR-H2 of SEQ ID NO: 80, and CDR-H3 of SEQ ID NO: 81, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 83, CDR-L2 of SEQ ID NO: 84, and CDR-L3 of SEQ ID NO: 85; or (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 82, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto, and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 86, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. The present invention relates to an anti-Nectin-4 antibody or an antigen-binding fragment thereof, comprising:

[0054] Antibody 9A2.7 is characterized by such VH and VL region sequences.

[0055] One embodiment comprises: (i) a VH region comprising CDR-H1 of SEQ ID NO: 87, CDR-H2 of SEQ ID NO: 88, and CDR-H3 of SEQ ID NO: 89, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 91, CDR-L2 of SEQ ID NO: 92, and CDR-L3 of SEQ ID NO: 93; or (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 90, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto, and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 94, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. The present invention relates to an anti-Nectin-4 antibody or an antigen-binding fragment thereof, comprising:

[0056] Antibody 3A1.4 is characterized by such VH and VL region sequences.

[0057] One embodiment comprises: (i) a VH region comprising CDR-H1 of SEQ ID NO: 95, CDR-H2 of SEQ ID NO: 96, and CDR-H3 of SEQ ID NO: 97, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 99, CDR-L2 of SEQ ID NO: 100, and CDR-L3 of SEQ ID NO: 101; or (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 98, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto, and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 102, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. The present invention relates to an anti-Nectin-4 antibody or an antigen-binding fragment thereof, comprising:

[0058] Antibody 8F06 is characterized by such VH and VL region sequences.

[0059] SEQ ID NOs:79-86 characterize mAb 9A2.7.

[0060] SEQ ID NOs:87-94 characterize mAb 3A1.4.

[0061] SEQ ID NOs: 95-102 characterize mAb 8F06.

[0062] In addition to lower binding affinity, the inventive antibodies and fragments provided herein also preferably exhibit lower internalization and / or lower cytotoxic activity towards keratinocytes compared to tumor cells.

[0063] According to a particularly preferred embodiment, the antibodies and fragments of the invention exhibit lower binding affinity, lower internalization and lower cytotoxic activity towards keratinocytes compared to tumor cells.

[0064] Of course, specific binding to tumor-expressed human nectin-4 is preferred, i.e., the antibodies provided herein preferably exhibit specific binding to nectin-4 and do not exhibit any intrinsic or cross-reactivity to other proteins, particularly proteins of the human nectin family such as nectin-1.

[0065] According to a further aspect, the present invention also relates to a monoclonal antibody or an antigen-binding fragment thereof, characterized in that it binds with higher affinity to human Nectin-4 expressed by tumors compared to Nectin-4 expressed by human differentiated keratinocytes, for comparison, the binding affinity can be detected by flow cytometry, immunohistochemistry and / or fluorescence.

[0066] According to a further embodiment, the antibody or antigen-binding fragment of the present invention comprises a labeling group and / or an effector group attached to the antibody or antigen-binding fragment. The labeling group can be, for example, a dye, a paramagnetic group, a radioactive group or a fluorescent group that is detectable during imaging. Preferred effector groups are therapeutic groups, in particular cytotoxic agents such as chemotherapeutic active agents, drugs, anti-inflammatory agents, radioisotopes, toxins such as topoisomerase poisons, enzymes such as nucleases and their fragments, growth inhibitors, antibiotics and all suitable anti-cancer and anti-tumor agents known to those skilled in the art. Particularly preferred is the topoisomerase poison camptothecin, and its derivatives and / or structural analogs such as exatecan and its derivatives such as deruxtecan.

[0067] Preferred embodiments of anti-tumor agents relate to anti-tumor immune stimulators, including but not limited to toll-like receptor (TLR) agonists or stimulator of interferon genes (STING) pathway.

[0068] According to another preferred embodiment, the anti-inflammatory agent may be selected from the group comprising steroids and glucocorticoids, for example corticosteroids such as cortisol and its derivatives, or mineralocorticoids, such as aldosterone and its derivatives.

[0069] According to a further aspect of the invention, the antibody or antigen-binding fragment thereof is for use in medicine, in particular for therapeutic or diagnostic uses, including in vitro and in vivo diagnostic uses.

[0070] The antibody or antigen-binding fragment thereof may be useful in methods for preventing and / or treating cancer and / or inflammatory disorders, wherein the cancer and / or inflammatory disorders are preferably associated with Nectin-4 overexpression.

[0071] The cancer to be prevented and / or treated may be any type of cancer, where the term "cancer" is used herein to refer to a proliferative disease. The cancer to be prevented and / or treated according to the present invention is preferably selected from the group consisting of urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, bladder cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer.

[0072] Being highly specific for Nectin-4 expressed on tumors, the antibodies and fragments thereof of the present invention may also be used in diagnostics, for example by binding to labeling groups as described above.

[0073] According to a further aspect, the antibody or antigen-binding fragment thereof described herein may be used in a method for preventing and / or treating an inflammatory disorder, which is preferably associated with Nectin-4 expression. Such treatment may preferably be combined with an anti-inflammatory agent known to those skilled in the art. Preferred anti-inflammatory agents are described above.

[0074] Another aspect of the present invention is a combination of at least two different monoclonal antibodies or fragments described herein.

[0075] Furthermore, the present invention relates to a nucleic acid molecule, e.g. a DNA molecule, encoding an antibody VH region, or an antibody VL region as indicated above, or encoding a complete antibody or an antibody fragment, or a vector or vector system, i.e. a plurality of vectors, comprising said nucleic acid molecule(s) as indicated above, preferably operably linked to an expression control sequence, in particular a heterologous expression control sequence.

[0076] Furthermore, the present invention relates to a cell comprising the above-mentioned nucleic acid molecule or vector or vector system. As used herein, the term "vector" refers to a nucleic acid molecule capable of amplifying another nucleic acid to which it is linked. According to a preferred embodiment, the vector is an expression vector. "Expression vectors" are capable of directing the expression of a nucleic acid to which they are operatively linked. Vectors, in particular expression vectors, for the recombinant production of antibodies are well known in the art.

[0077] The cell can be any host cell known for producing antibodies or antibody fragments, for example a prokaryotic cell such as an E. coli cell, a yeast cell, an insect cell, or a mammalian cell, for example a CHO cell or a hybridoma cell.

[0078] Yet another aspect of the present invention relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof described herein.Typically, the antibody or antibody fragment is administered as a pharmaceutical composition comprising an active agent and a pharma-ceutically acceptable carrier or excipient.Examples of suitable carriers and excipients for formulating the antibody or antibody fragment include saline and aqueous buffer solutions and are well known in the art.

[0079] Depending on the stage and severity of the disorder to be treated, the pharmaceutical composition may be administered once or several times during the course of the disorder, for example, it may be administered daily, every other day, twice a week or once a week for a suitable period of time.

[0080] In certain embodiments, the pharmaceutical compositions are administered parenterally, for example by subcutaneous, intramuscular or intravenous injection or by infusion, hi further embodiments, the pharmaceutical compositions may be administered topically, for example orally, to the nose or to the lungs, for example as an aerosol.

[0081] The invention is further illustrated in more detail by the following tables, figures and examples. [Brief description of the drawings]

[0082] [Figure 1]Ch-15A7.5 recognizes human nectin-4. Detection by flow cytometry. Flow cytometric analysis of MDA-MB231 transfected with an N-terminal Flag-tagged epitope of nectin-4 using a range of doses of Ch-15A7 antibody (0.3 ng / mL - 5 μg / mL). Parental MDA-MB231 cells are included as a control. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. Inlay: staining of parental MDA-MB231 cells with anti-nectin-1, -2 and -3 mAb (5 μg / mL). Mean fluorescence intensity is represented. [Diagram 2] Ch-15A7.5 recognizes the IgV-like domain of human nectin-4. Detection by ELISA. 96-well plates were coated overnight at 4° C. with 5 μg / mL of nectin-1 extracellular domain Fc fusion recombinant protein (Nec1-VCC), or nectin-4 IgV-like domain Fc fusion recombinant protein (Nec4-V), or nectin-4 extracellular domain Fc fusion recombinant protein (Nec4-VCC), as indicated. Ch15A7.5 recognizes the nectin-4 extracellular domain, more precisely the nectin-4 IgV-like domain, but not the nectin-1 extracellular domain. [Diagram 3] Characterization of the Ch-15A7.5 epitope. Competitive assays were performed by ELISA. 96-well plates were coated with 5 μg / mL of Nectin-4 extracellular domain Fc fusion recombinant protein (Nec4-VCC) overnight at 4 °C. Binding of peroxidase-conjugated Ch-15A7.5 mAb (5 μg / mL) was measured in the presence of increasing concentrations (2.75 ng / mL to 6 μg / mL) of Rituximab, Ch-15A7 mAb, Enfortumab (HA22), Ch-N41 mAb and Ch-14A5 mAb. HA22, Ch-N41 and CH-14A5 recognize the IgV domain of Nectin-4. [Figure 4]Competition of Ch-15A7.5 mAb with Nectin-1 for Nectin-4 binding. Competition was assessed by flow cytometry. 50,000 CHO cells transfected with human Nectin-4 cDNA were seeded in 96-well plates. Cells were incubated with increasing concentrations (8 ng / mL to 5 μg / mL) of isotype control or Ch-15A7.5 mAb for 45 min. After washing, plates were incubated with 20 μg / mL of Nectin-1 extracellular domain Fc fusion recombinant protein (Nec1-VCC). Nectin-1 binding was revealed after incubation with goat anti-human Fc antibody conjugated to phycoerythrin. [Diagram 5] Cross-reactivity with Nectin-4 from cynomolgus monkeys, rats and mice. Detection by flow cytometry. Flow cytometric analysis of CHO cells transfected with human, cynomolgus monkeys, rats or mice Nectin-4 using a range of doses (0.05 ng / mL - 5 μg / mL) of Ch-15A7 (A), Ch-3A1.4 (B), Ch-9A2.7 (C) or Enfortumab (HA22, D) antibodies. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. The table reports estimated EC50 values ​​determined by GraphPad Prism 9 software using nonlinear curve fitting (4 parameters). The ~ symbol indicates that the reported value is ambiguous due to poor curve fitting. [Figure 6]Differential binding to nectin-4 expressed by tumor cell lines and normal differentiated human keratinocytes. Detection by flow cytometry. Flow cytometric analysis of TNBC cell lines (SUM190, filled symbols) and normally differentiated (0.1 mM CaCl2) human keratinocytes (NHEK, open symbols) using a range of doses (1.2 ng / mL to 5 μg / mL) of enfortumab (HA22, squares), Ch-15A7.5 (circles), Ch-3A1.4 (triangles) and Ch-9A2.7 (diamonds). Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. Nonlinear curve fitting (4 parameters) was performed using GraphPad Prism 9 software. The horizontal bar is placed at 50% of the maximum staining intensity obtained with HA22 antibody on SUM190 cells. [Figure 7] Differential binding to nectin-4 expressed by tumor cell lines and normally differentiated human keratinocytes. Detection by flow cytometry. Flow cytometric analysis of TNBC cell line (SUM190, A) and normally differentiated (0.1 mM CaCl2) human keratinocytes (NHEK, B) using 5 μg / mL of HA22 (enfortumab), Ch-15A7.5, and Ch-8F06. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. [Figure 8] Differential binding to nectin-4 expressed by tumor cell lines and human keratinocytes. Detection by immunohistochemistry. Cryopreserved OCT-embedded blocks of a high-expressing nectin-4 tumor cell line (SUM190), a low-expressing nectin-4 tumor cell line (SUM149), human and cynomolgus skin were processed for staining with 15A7.5 mAb (A) and 9A2.7 mAb (B). The reported quick scores for each mAb are shown (A, B). C, Ratio of quick scores SUM190 on human skin. [Figure 9]Differential internalization in tumor cell lines and human keratinocytes. Detection by fluorescence. Enfortumab (HA22), Ch-15A7.5 and isotype control mAb were conjugated to pHAB thiol-reactive dye to reach dye-antibody ratios between 4.58 and 5.55. A range of doses (1.6ng / mL to 5μg / mL) of each of these antibody-dye conjugates were incubated in duplicate with SUM190PT nectin-4 expressing cell line (A) and normal human differentiated (0.1mM CaCl2) keratinocytes (B). Intracellular fluorescence was recorded after 24 hours with a fluorescence microplate reader (ClarioStar). Fluorescence intensity is reported as a function of dye-antibody conjugate concentration. [Figure 10] Differential in vitro cytotoxic activity against tumor cells and normal differentiated human keratinocytes. Cell viability measured by MTT assay. Enfortumab (HA22, diamonds), Ch-15A7.5 (triangles) and Ch-9A2.7 (squares) mAbs were conjugated with α-amanitin to generate antibody-drug conjugates and their cytotoxic activity in a dose range (7.7 pg / mL-15 μg / mL) was comparatively evaluated against SUM190PT nectin-4 expressing cell line (A, D) or normal human differentiated (0.1 mM CaCl2) keratinocytes (B, E). Viability (MTT assay) after a 5-day incubation period is reported. EC50 values ​​were determined by GraphPad Prism 9 software using nonlinear curve fitting (4 parameters). For each condition, the ratio of EC50 of Ch-15A7.5 ADC (C) or Ch-9A2.7 ADC (F) to EC50 of HA22-ADC was calculated and reported. Data shown are representative of three independent donors for two different Nectin-4 expressing tumor cell lines (SUM190PT and MDA-MB468) and human keratinocytes. [Figure 11]Treatment of NSG mice implanted with SUM190 with Ch-15A7.5-MA-PS-βGlu-exatecan ADC induces a durable period of tumor regression. NSG mice (n=5 / group) were orthotopically xenografted bilaterally with SUM190PT cells embedded in Matrigel. Three different ADCs were tested: isotype controls ICT-MA-PS-βGlu-exatecan and Ch-15A7.5-MA-PS-βGlu-exatecan, as well as the enfortumab vedotin surrogate HA22-MC-vc-PABC-MMAE. Treatment of mice (single intravenous injection) began when tumors reached approximately 150 mm3. Ch-15A7.5-MA-PS-βGlu-exatecan (Ch-15A7.5-Ex) was evaluated at two doses (4 or 8 mg / kg), ICT-MA-PS-βGlu-exatecan (ICT-Ex) was given at 8 mg / kg, and enfortumab vedotin (EV) surrogate was given at 4 mg / kg. Tumor size (n=10 / group) was monitored twice weekly thereafter with calipers and size was reported using the following formula (L×l×h×Pi / 6). [Figure 12] Apparent affinity of humanized variants for tumor cells. Detection by flow cytometry. T47D human tumor cells expressing Nectin-4 were numbered and incubated with a range of doses (169 pg / mL to 30 μg / mL) of Ch-15A7.5 or the indicated humanized variants. Numbers associated with H and L refer to the number of backmutations introduced. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody and analyzed by flow cytometry. Mean fluorescence intensity is reported. GraphPad Prism 9 software used nonlinear curve fitting (4 parameters). [Figure 13]Treatment of NSG mice implanted with SUM190 with HA22-MA-PS-βGlu-E-exatecan ADC induces a durable period of tumor regression. NSG mice (n=5 / group) were orthotopically xenografted bilaterally with SUM190PT cells embedded in Matrigel. Three different ADCs were tested: isotype controls ICT-MA-PS-βGlu-exatecan and HA22-MA-PS-βGlu-exatecan, as well as the enfortumab vedotin surrogate HA22-MC-vc-PABC-MMAE. Treatment of mice (single intravenous injection) began when tumors reached approximately 150 mm3. HA22MA-PS-βGlu-exatecan (HA22-Ex) was evaluated at two doses (4 or 8 mg / kg), ICT-MA-PS-βGlu-exatecan (ICT-Ex) was given at 8 mg / kg, and enfortumab vedotin (EV) surrogate was given at 4 mg / kg. Tumor size (n=10 / group) was monitored twice weekly thereafter with calipers and size was reported using the following formula (L×l×h×Pi / 6). [Figure 14]Treatment of NSG mice implanted with SUM190 with HA22-MA-PS-βGlu-E-exatecan and HA22-MC-GGFG-DX8951 ADCs induces a long-lasting period of tumor regression. NSG mice (n=5 / group) were orthotopically xenografted bilaterally with SUM190PT cells embedded in Matrigel. Five different ADCs were tested: isotype controls, ICT- and HA22 combined with either MA-PS-βGlu-exatecan (ICT-Ex and HA22-Ex) or MC-GGFG-DX8951 (ICT- and HA22-Dxd), and the enfortumab vedotin surrogate, HA22-MC-vc-PABC-MMAE (EV). Treatment of mice (single intravenous injection) began when tumors reached approximately 150 mm3. HA22-Ex and HA22-Dxd were evaluated at two doses (4 or 8 mg / kg), ICT-EX and ICT-Dxd were given at 8 mg / kg, and enfortumab vedotin (EV) surrogate was given at 4 mg / kg. Tumor size (n=10 / group) was subsequently monitored twice weekly with calipers and size was reported using the following formula (L×l×h×Pi / 6). [Figure 15] Treatment of NOD-Scid mice implanted with SUM190 with Ch-15A7.5-α-amanitin ADC induces a long-lasting period of tumor regression. NOD-Scid mice (n=10 / group) were orthotopically xenografted with SUM190PT cells embedded in Matrigel. Three different ADCs were tested: isotype controls ICT-α-amanitin and Ch-15A7.5-α-amanitin, as well as the enfortumab vedotin surrogate HA22-MC-vc-PABC-MMAE (EV surrogate). Treatment of mice (two intravenous injections 7 days apart, arrowheads) began when tumors reached approximately 120 mm3. Ch-15A7.5-α-amanitin was evaluated at two doses (0.5 or 1 mg / kg), ICT-α-amanitin was given at 1 mg / kg, and enfortumab vedotin (EV) surrogate was given at 0.5 or 2 mg / kg. Tumor size (n=10 / group) was subsequently monitored twice weekly with calipers and size was reported using the following formula (L×l×h×Pi / 6). [Figure 16] Treatment of NOD-Scid mice implanted with SUM190 with HA22-α-amanitin ADC induces a durable period of tumor regression. NOD-Scid mice (n=10 / group) were orthotopically xenografted with SUM190PT cells embedded in Matrigel. Three different ADCs were tested: isotype controls ICT-α-amanitin and HA22-α-amanitin, as well as the enfortumab vedotin surrogate HA22-MC-vc-PABC-MMAE (EV surrogate). Treatment of mice (two intravenous injections, 7 days apart; arrowheads) began when tumors reached approximately 120 mm3. HA22-α-amanitin was evaluated at two doses (0.5 or 1 mg / kg), ICT-α-amanitin given at 1 mg / kg, and enfortumab vedotin (EV) surrogate given at 0.5 or 2 mg / kg. Tumor size (n=10 / group) was monitored twice weekly thereafter with calipers and sizes were reported using the following formula (L×l×h×Pi / 6). [Figure 17] Treatment of NOD-Scid mice implanted with SUM190 with Ch-15A7.5-α-amanitin ADC induces a durable period of tumor regression. NOD-Scid mice (n=10 / group) were orthotopically xenografted with SUM190PT cells embedded in Matrigel. Three different ADCs were tested: isotype controls ICT-α-amanitin and Ch-15A7.5-α-amanitin, as well as the enfortumab vedotin surrogate HA22-MC-vc-PABC-MMAE (EV surrogate). Treatment of mice (single intravenous injection, arrowhead) began when tumors reached approximately 120 mm3. Ch-15A7.5-α-amanitin was evaluated at three doses (2, 4 and 8 mg / kg), ICT-α-amanitin was given at 8 mg / kg, and enfortumab vedotin (EV) surrogate was given at 4 mg / kg. Tumor size (n=10 / group) was subsequently monitored twice weekly with calipers and size was reported using the following formula (L×l×h×Pi / 6). [Figure 18]Treatment of NOD-Scid mice implanted with SUM190 with HA22-α-amanitin ADC induces a durable period of tumor regression. NOD-Scid mice (n=10 / group) were orthotopically xenografted with SUM190PT cells embedded in Matrigel. Three different ADCs were tested: isotype controls ICT-α-amanitin and HA22-α-amanitin and the enfortumab vedotin surrogate HA22-MC-vc-PABC-MMAE (EV surrogate). Treatment of mice (single intravenous injection, arrowhead) began when tumors reached approximately 120 mm3. Three doses of HA22-α-amanitin were evaluated (2, 4 and 8 mg / kg), with ICT-α-amanitin given at 8 mg / kg and the enfortumab vedotin (EV) surrogate given at 4 mg / kg. Tumor size (n=10 / group) was monitored twice weekly thereafter with calipers and sizes were reported using the following formula (L×l×h×Pi / 6). [Figure 19] Differential binding of Ch-15A7.5 and its humanized variants to nectin-4 expressed by tumor cell lines and normally differentiated human keratinocytes. Detection by flow cytometry. Flow cytometric analysis of TNBC cell lines (SUM190, top panel) and normally differentiated (0.1 mM CaCl2) human keratinocytes (NHEK, bottom panel) using a range of doses (8 pM to 33 nM) of Ch-5A12.2, Ch-15A7.5 and its humanized variants 15A7.5-H1L2, -H1L3, -H2L2, -H2L3, -H3L0, -H3L2, -H3L3. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. Nonlinear curve fitting (4 parameters) was performed using GraphPad Prism 9 software. Note the much lower apparent EC50 of Ch-15A7.5 and its humanized variants against keratinocytes (bottom panel) compared to the EC50 of Ch-5A12.2. [Figure 20] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the parent antibody clone 5A12.2. The H-CDR and L-CDR sequences according to the IMTG nomenclature are underlined. [Figure 21] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the humanized variants of 9A2.7. The H-CDR and L-CDR sequences according to the IMTG nomenclature are underlined. [Figure 22] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the humanized variants of 3A1.4. The H-CDR and L-CDR sequences according to the IMTG nomenclature are underlined. [Diagram 23] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the humanized variants of 8F06. The H-CDR and L-CDR sequences according to the IMTG nomenclature are underlined. [Figure 24] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the parent antibody clone 15A7.5. The H-CDR and L-CDR sequences according to the IMTG nomenclature are shaded in grey. [Diagram 25] Amino acid sequences of the variable heavy (VH) and variable light (VL) chains of the humanized variant of 15A7.5. The H-CDR and L-CDR sequences according to the IMTG nomenclature are shaded in grey. [Figure 26] Affinity values ​​of humanized 15A7.5 variants EXAMPLES

[0083] material and method Cell line: Human breast cancer cell line MDA-MB231 (ATCC, Manassas, VA) was cultured in DMEM supplemented with 10% fetal bovine serum, 50 IU / mL penicillin, 50 μg / mL streptomycin and 2 mM glutamine. Cells were transfected with expression vector p3XFLR4.C1 containing PVRL4 cDNA. Human triple-negative breast cancer cell line SUM190PT (BioIVT, Westbury, NY) was cultured in Ham's F12 medium with 5% fetal bovine serum, 1% non-essential amino acids, 1% Hepes, 1% insulin, 1 μg / mL hydrocortisone, 6.8 ng / mL triiodo-L-tyrosine, 100 IU / mL penicillin, 100 μg / mL streptomycin and 2 mM glutamine. Chinese hamster ovary CHO cell lines were cultured in DMEM supplemented with 10% fetal bovine serum, 100 IU / mL penicillin, 100 μg / mL streptomycin, and 2 mM glutamine. Human breast cancer MDA-MB-468 and T47D cell lines were cultured in RPMI supplemented with 10% fetal bovine serum, 100 IU / mL penicillin, and 100 μg / mL streptomycin.

[0084] ELISA: A sandwich enzyme-linked immunosorbent assay was used to control the specificity of the Ch-15A7.5 antibody and to perform competition assays between the different mabs. 96-well plates were coated overnight at +4°C with 10 nM of Nectin-4-VCC-Fc, Nectin-1-VCC-Fc (whole extracellular part) or Nectin-4-V-Fc (containing only the IgV domain). After washing and saturation with PBS 1% BSA, cells were incubated with 10 nM of peroxidase-conjugated Ch-15A7.5 mab for 2 h at 25°C. In the case of competition, binding of 0.5 nM of peroxidase-conjugated Ch-15A7.5 mab was measured in the presence of variable concentrations (0.018 nM to 40 nM) of "cold" mab. 100 μL of peroxidase substrate was added (One Step ABST, Pierce) and OD was read at 405 nm.

[0085] Flow cytometry: Cells or cell lines expressing Nectin-4 (native or transfected) (10,000-50,000) were incubated with a dose range of the indicated antibodies. After washing, cells were then stained with phycoerythrin-conjugated goat anti-human antibody (5 μg / mL, Jackson Immuno Research). After fixation, cells were stained with a viability dye (e780, Invitrogen) prior to flow cytometry acquisition.

[0086] Immunohistochemistry: Frozen samples stored at -80°C were kept on dry ice, placed in plastic cryomolds to allow for maximizing the number of subsequent sections, and embedded in Optimal Cutting Temperature (OCT) medium. Frozen blocks of OCT were mounted on OCT disks and cryosectioning was performed at -20°C on a NX70 cryostat (Thermo Scientific). Frozen sections (7 μm) were mounted on Superfrost Plus slides (VWR). Only the number of slides required for each series of studies were prepared and stored at -80°C until use. The remaining blocks were stored at -80°C until further use. Sections were placed on slides and fixed in acetone at -20°C for 10 minutes. As part of the Roche DAB kit protocol, endogenous peroxidase was inhibited by immersing the slides in hydrogen peroxide (H2O2). Several dilutions of each mab were tested to optimize the signal-to-noise ratio, and 0.5 μg / mL of mouse 15A7.5 mab and 10 μg / mL of mouse 9A2.7 mab were determined as optimal. To reduce non-specific binding of the secondary antibody to mouse tissues, rabbit anti-mouse IgG (4 μg / mL, Abcam) was added after the primary Ab incubation. DAB staining was then performed using omni-map anti-rabbit HRP (Roche) according to the manufacturer's instructions (Ventana automat). Evaluation of both staining intensity and proportion of stained cells was performed. Two trained technicians independently and sequentially observed the same microscopic fields. Both the proportion of stained cells and staining intensity were evaluated for each field. For each staining, 10 fields were randomly selected at the magnification that allowed the best visualization of the tissue. The scoring procedure was as follows: (i) the proportion of positively stained cells was estimated and assigned a score of 0 to 4 for each field (0 = 0-5%; 1 = 5-25%; 2 = 25-50%; 3 = 50-75%; and 4 = 75-100%); and (ii) the staining intensity was scored as 0, 1, 2, or 3, corresponding to the presence of negative, weak, intermediate, and strong brown staining, respectively.The final score for each field and each observer was a multiplication of the two values ​​(0 = no staining in the tissue; 12 = tissue contains strongly stained cells). For each tissue type, 10 independent fields were scored in parallel for each of the five slides in each slide set for both staining intensity and percentage of labeled cells. Technicians simultaneously viewed a given field (virtual slide, on a computer screen) and scored independently, blinded to the results of the other observer. For each slide, the 10 scores of each technician were averaged to establish a final score for each observer. The final scores of the two observers were averaged to obtain the tissue score for a given slide. For human skin, only the results of the first set of reproducibility are presented.

[0087] Internalization assay Ten thousand SUM190PT or human differentiated keratinocytes (0.1 mM CaCl2) were seeded in 96-well plates and subsequently incubated with a range of doses (1.6 ng / mL-5 μg / mL) of anti-nectin-4 mAb conjugated with pHAB thiol-reactive dye and isotype control for 24 h at 37 °C. After internalization and endolysosomal processing, the acidic environment causes the dye to fluoresce. Fluorescence intensity was monitored on a plate reader at an excitation wavelength of 532 nm and an emission wavelength of 560 nm.

[0088] In vitro cytotoxicity assay To analyze the in vitro cytotoxic activity of ADCs, cell viability was assessed using the AlamarBlue staining protocol recommended by the manufacturer (Biosource, CA, USA). The test incorporates a fluorescent redox indicator. Fluorescence intensity is proportional to the metabolic decline of cells. Experiments were performed by incubating 3000 cells / well (SUM190PT or differentiated NHEK) in triplicate with serial dilutions of ADCs on day 0 in 96-well plates. AlamarBlue was measured on day 5 by incubating 1 / 10 volume of alamarBlue solution at 37°C for 2 hours and reading at 595 nm (FLUOstar Optima, BMG Labtech).

[0089] Mouse experiments NOD / SCID (non-obese diabetic / severe combined immunodeficiency) / gc null mice (NSG) were obtained from Charles River Laboratory (Margate, UK). Six to seven week old females (n = 5 / group) were treated with 0.5 × 10 IgG1-embedded SUM190PT (0.5 × 10 6 10) cells were xeno-implanted orthotopically on both sides. Treatment with ADC was performed as mentioned in each experiment. Tumor size (n=10 / group) was monitored twice a week thereafter with calipers, and size was reported using the following formula (L×l×h×Pi / 6).

[0090] Hybridoma sequencing For hybridoma sequencing, RNA was first extracted from hybridoma cell pellets. cDNA was generated by reverse transcription, and the VH and VL domains were amplified by polymerase chain reaction using Prime STARMax DNA Polymerase (Takara). The PCR products were subsequently cloned into dedicated heavy and light chain expression vectors and then sequenced.

[0091] Generation, production, purification and control of chimeric antibodies The light chain expression vector encodes the V kappa chain. Depending on the payload used, two different heavy chain expression vectors were used: one encoding an Fc fragment with the mutations D265C (ThiomAb) L234A and L235A, and the other encoding an Fc fragment with the mutations P331S, L234Q and L235F. Both Fc fragments are "Fc silent". The sequence of anti-nectin-4 Enfortumab (HA22) was also cloned into the same vector.

[0092] Light and heavy chain vectors were transfected into HEK293 seeded at a ratio of 1.2 / 1. After 6 days of production, culture supernatants were clarified and mAbs were purified using MabSelect PrismA resin (GE Healthcare) according to the manufacturer's instructions. 0.5 M glycine, 3 M NaCl, pH 8.9 was used as binding buffer and 0.1 M citric acid pH 3 was used for elution. Immediate neutralization was performed with 10% (V / V) 1 M Tris-HCl pH 9. Monoclonal chimeric antibodies were then dialyzed against PBS 1× pH 7.4 (Mini dialysis devices, 2 mL-10k, Thermo Scientific) and then filtered on a 0.22 μM filter (Milelex GV hydrophilic PVDF, Millipore). Concentrations were calculated based on the specific extinction coefficient (E 1% 280nm) was determined using a Nanodrop 2000 Spectrophotometer (Thermo Scientific). Purity was determined by UPLC-SEC using an Acquity UPLC-HClass Bio (Waters) using a Protein-BEH 200A column equilibrated in 0.2 M NaPO4, 0.3 M NaCl pH 6.9 supplemented with 10% isopropanol. Antibody mass was determined in a Xevo G2-S Q-Tof mass spectrometer (Waters) using a reversed-phase column (PLRP-S 4000A, Agilent technologies). All samples were analyzed after deglycosylation with PNGase F glycosidase (New England Biolabs) at 37°C according to the manufacturer's instructions. Fragmentation and / or aggregation of the final material was assessed by SDS-PAGE. Endotoxin load was determined using a chromogenic LAL-kinetic assay (Charles River Endosafe).

[0093] Antibody Conjugation The thiol-reactive dye pHAB (Promega) was conjugated to the cysteines of selected anti-Nectin-4 ThiomAb (D265C, L234A, L235A) antibodies using maleimide chemistry according to the manufacturer's instructions. Briefly, the antibodies were reduced at 2.5 mM for 1 h at room temperature under gentle agitation after dialysis against 0.1 M phosphate buffer pH 7.0. Subsequently, DTT was removed by washing / centrifugation twice on a Zeba spin desalting column (7 MWCO). 1.2 L of pHdye reagent (10 μg / mL DMSO) was added to 100 μg of antibody and incubated at room temperature for 1 h protected from light. After removal of excess dye on a Zeba desalting column, the dye-antibody ratio was calculated to confirm equivalent conjugation between the different antibodies.

[0094] Cysteine-reactive linker-amanitin compounds (Heidelberg Pharma) with cleavable linkers (valine alanine) or non-cleavable linkers were conjugated to engineered cysteine ​​residues of selected anti-nectin-4 ThiomAb (D265C, L234A, L235A) antibodies using maleimide chemistry. Briefly, Thiomab antibodies in PBS 1× pH 7.4 were reduced with TCEP and the interchain disulfides were reoxidized with dehydroascorbic acid. The engineered cysteines were subsequently used for conjugation with the cysteine-reactive linker, amanitin compound HDP 30.1699. The conjugates were purified by dialysis. The drug-antibody ratio (DAR) by LC-MS analysis was between 1.44 and 1.79 toxins per conjugated mAb. Less than 2% of the material was aggregated as determined by SEC-HPLC.

[0095] The cysteine ​​reactive linker-exatecan compound maleimide-Gly-PSAR10-glucuronide-exatecan (MabLink) was conjugated to the cysteine ​​residues of selected anti-nectin-4 mAbs (P331S, L234Q and L235F). Briefly, the mAbs in PBS 1×, 1 mM EDTA were reduced with 14 molar equivalents of TCEP for 2 hours at 37° C., after which the buffer was exchanged into 100 mM KPO4, 1 mM EDTA pH 7.4 (Amicon ultra 30 kDa). 12 molar equivalents of the cysteine ​​reactive linker-exatecan compound were used to conjugate with the reactive cysteine ​​for 35 minutes at room temperature. The buffer was then exchanged into 100 mM KPO4 pH 8.0, followed by incubation for 24 hours at 37° C. in the absence of oxygen to allow autohydrolysis of the maleimide. A final buffer exchange was performed in 20 mM His pH 6.0 followed by filtration through a 0.22 μM filter. The drug-to-antibody ratio (DAR) by LC-MS analysis was between 7.77 and 7.82 toxins per conjugated mAb. Less than 8% of the material was aggregated as determined by SEC-HPLC. The invention as originally claimed in the present application is set forth below. [1] (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 comprises an amino acid sequence according to SEQ ID NO: 1, 7, 79, 87 or 95 or an amino acid sequence comprising a substitution, in particular a conservative substitution of one or two amino acids, (ii) the CDR-H2 comprises an amino acid sequence according to SEQ ID NO: 2, 8, 80, 88 or 96 or an amino acid sequence containing a substitution, in particular a conservative substitution of one or two amino acids, (iii) a VH region, the CDR-H3 of which comprises an amino acid sequence according to SEQ ID NO: 3, 9, 81, 89 or 97, or an amino acid sequence containing a substitution, in particular a conservative substitution of one or two amino acids, and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 comprises an amino acid sequence according to SEQ ID NO: 4, 10, 83, 91 or 99, or an amino acid sequence comprising a substitution, in particular a conservative substitution of one or two amino acids, (ii) the CDR-L2 comprises an amino acid sequence according to SEQ ID NO: 5, 11, 84, 92 or 100, or an amino acid sequence containing a substitution, in particular a conservative substitution of one or two amino acids, (iii) A monoclonal antibody or an antigen-binding fragment thereof that binds to Nectin-4, comprising a VL region, wherein the CDR-L3 comprises an amino acid sequence according to SEQ ID NO: 6, 12, 85, 93 or 101, or an amino acid sequence containing a substitution, particularly a conservative substitution of one or two amino acids. [2] (i) a VH region comprising CDR-H1 of SEQ ID NO: 1, CDR-H2 of SEQ ID NO: 2, and CDR-H3 of SEQ ID NO: 3, and optionally (ii) The antibody or antigen-binding fragment of [1], comprising a VL region comprising CDR-L1 of sequence number 4, CDR-L2 of sequence number 5, and CDR-L3 of sequence number 6. [3] (i) a VH region comprising CDR-H1 of SEQ ID NO: 7, CDR-H2 of SEQ ID NO: 8, and CDR-H3 of SEQ ID NO: 9, and optionally (ii) The antibody or antigen-binding fragment of [1] or [2], comprising a VL region comprising CDR-L1 of SEQ ID NO: 10, CDR-L2 of SEQ ID NO: 11, and CDR-L3 of SEQ ID NO: 12. [4] (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 13, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto, and optionally (b) An antibody or antigen-binding fragment according to any one of [1] to [3], comprising a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 14, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto. [5] (i) a VH region comprising CDR-H1 of SEQ ID NO: 79, CDR-H2 of SEQ ID NO: 80, and CDR-H3 of SEQ ID NO: 81, and optionally (ii) The antibody or antigen-binding fragment of [1], comprising a VL region comprising CDR-L1 of SEQ ID NO: 83, CDR-L2 of SEQ ID NO: 84, and CDR-L3 of SEQ ID NO: 85. [6] (i) a VH region comprising CDR-H1 of SEQ ID NO: 87, CDR-H2 of SEQ ID NO: 88, and CDR-H3 of SEQ ID NO: 89, and optionally (ii) The antibody or antigen-binding fragment of [1], comprising a VL region comprising CDR-L1 of SEQ ID NO: 91, CDR-L2 of SEQ ID NO: 92, and CDR-L3 of SEQ ID NO: 93. [7] (i) a VH region comprising CDR-H1 of SEQ ID NO: 95, CDR-H2 of SEQ ID NO: 96, and CDR-H3 of SEQ ID NO: 97, and optionally (ii) The antibody or antigen-binding fragment of [1], comprising a VL region comprising CDR-L1 of SEQ ID NO: 99, CDR-L2 of SEQ ID NO: 100, and CDR-L3 of SEQ ID NO: 101. [8] (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 82, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto, and optionally (b) An antibody or antigen-binding fragment of any of [1] or [5], comprising a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 86, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. [9] (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 90, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto, and optionally (b) An antibody or antigen-binding fragment of any of [1] or [6], comprising a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 94, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto.

[10] (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 98, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto, and optionally (b) An antibody or antigen-binding fragment of any of [1] or [7], comprising a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 102, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto.

[11] An antibody or antigen-binding fragment of any of [1] to

[10] , which is a chimeric antibody, a multispecific antibody, particularly a bispecific antibody, a human antibody, a humanized antibody, or an antigen-binding fragment thereof.

[12] An antibody or antigen-binding fragment thereof according to any one of [1] to

[11] , which is an antibody of class IgG, e.g., subclass IgG1, IgG2, IgG3, or IgG4, class IgM, class IgA, or an antigen-binding fragment thereof, or which is a single-chain antibody, or an antibody Fv fragment.

[13] (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 comprises an amino acid sequence according to SEQ ID NO: 21, 35, 49 or 63, or an amino acid sequence comprising a substitution, in particular a conservative substitution of one or two amino acids, (ii) the CDR-H2 comprises an amino acid sequence according to SEQ ID NO: 22, 36, 50 or 64 or an amino acid sequence containing a substitution, in particular a conservative substitution of one or two amino acids, (iii) a VH region, the CDR-H3 of which comprises an amino acid sequence according to SEQ ID NO: 23, 37, 51 or 65, or an amino acid sequence containing a substitution, in particular a conservative substitution of one or two amino acids, and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 comprises an amino acid sequence according to SEQ ID NO: 24, 38, 52 or 66, or an amino acid sequence comprising a substitution, in particular a conservative substitution of one or two amino acids, (ii) the CDR-L2 comprises an amino acid sequence according to SEQ ID NO: 25, 39, 53 or 67, or an amino acid sequence containing a substitution, in particular a conservative substitution of one or two amino acids, (iii) The antibody or antigen-binding fragment of any one of [1] to [4],

[11] or

[12] , comprising a VL region, wherein the CDR-L3 comprises an amino acid sequence according to SEQ ID NO: 26, 40, 54 or 68, or an amino acid sequence comprising a substitution, particularly a conservative substitution of one or two amino acids.

[14] (a)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (b)(i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (c) (i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54; or (d)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67 and CDR-L3 of SEQ ID NO: 68; (e) (i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53 and CDR-L3 of SEQ ID NO: 54; (f)(i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67 and CDR-L3 of SEQ ID NO: 68, or (g)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 41, and CDR-H3 of SEQ ID NO: 42, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67 and CDR-L3 of SEQ ID NO: 68; (h) (i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65, and optionally (ii) An antibody or antigen-binding fragment of any of [1] to [4],

[11] ,

[12] or

[13] , comprising a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54.

[15] (i) a VH region comprising an amino acid sequence selected from SEQ ID NO: 27, 41, 55, or 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto, and optionally (ii) An antibody or antigen-binding fragment of any of [1] to [4] and

[11] to

[14] , comprising a VL region, particularly a VL region comprising an amino acid sequence selected from SEQ ID NO: 28, 42, 56, or 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[16] (a)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto, and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (b)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto, and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (c)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof, and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (d)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof, and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (e) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof, and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (f) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof, and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (g)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof, and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (h)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof, and optionally (ii) An antibody or antigen-binding fragment of any of [1] to [4] and

[11] to

[15] , comprising a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto.

[17] An antibody or antigen-binding fragment of any of [1]-

[16] that binds with higher affinity to Nectin-4 expressed by tumors compared to Nectin-4 expressed by human differentiated keratinocytes.

[18] An antibody or antigen-binding fragment of

[17] , wherein the binding affinity is detected by flow cytometry, immunohistochemistry and / or fluorescence.

[19] A monoclonal antibody or antigen-binding fragment thereof that binds with higher affinity to Nectin-4 expressed by tumors compared to Nectin-4 expressed by human differentiated keratinocytes.

[20] The monoclonal antibody or antigen-binding fragment thereof described in

[20] , wherein the binding affinity is detected by flow cytometry, immunohistochemistry and / or fluorescence.

[21] An antibody or antigen-binding fragment of any of [1] to

[20] , which comprises a labeling group and / or an effector group bound to the antibody or antigen-binding fragment.

[22] The antibody or antigen-binding fragment of

[21] , wherein the labeling group is a dye, a paramagnetic group, a radioactive group or a fluorescent group that is detectable upon imaging.

[23] The antibody or antigen-binding fragment of

[21] , wherein the effector group is a therapeutic group, particularly a cytotoxic agent.

[24] An antibody or fragment of any of [1]-

[23] for use in medicine, in particular for therapeutic or diagnostic applications, including in vitro and in vivo diagnostic applications.

[25] An antibody or fragment of any of [1] to

[23] for use as described in

[18] in a method for preventing and / or treating cancer and / or inflammatory disorders.

[26] An antibody or fragment of any of [1] to

[23] for use according to

[24] or

[25] , wherein the cancer is associated with overexpression of Nectin-4.

[27] An antibody or fragment of any of [1] to

[23] for use according to any of

[24] to

[26] , wherein the cancer is urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer.

[28] A combination of at least two different monoclonal antibodies or fragments described in any of [1] to

[23] .

[29] A nucleic acid encoding one or more of the antibodies described in any one of [1] to

[23] , or at least one VL and / or one VH of any one of the antibodies of [1] to

[23] .

[30] A vector comprising the nucleic acid described in

[29] .

[31] A host cell containing the vector

[30] .

[32] A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof described in any one of [1] to

[27] .

Claims

1. (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO:1; (ii) the CDR-H2 comprises the amino acid sequence set forth in SEQ ID NO:2; (iii) a VH region, wherein the CDR-H3 comprises the amino acid sequence set forth in SEQ ID NO:3; and (b) a variable light chain (VL) region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 comprises the amino acid sequence set forth in SEQ ID NO:4; (ii) the CDR-L2 comprises the amino acid sequence set forth in SEQ ID NO:5; (iii) a VL region, wherein the CDR-L3 comprises the amino acid sequence set forth in SEQ ID NO:

6. Contains or (c) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO:7; (ii) the CDR-H2 comprises the amino acid sequence set forth in SEQ ID NO:8; (iii) a VH region, wherein the CDR-H3 comprises the amino acid sequence set forth in SEQ ID NO:9; and (d) a variable light chain (VL) region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 comprises the amino acid sequence set forth in SEQ ID NO:10; (ii) the CDR-L2 comprises the amino acid sequence set forth in SEQ ID NO:11; (iii) the CDR-L3 comprises a VL region comprising the amino acid sequence set forth in SEQ ID NO: 12; A monoclonal antibody or an antigen-binding fragment thereof that binds to Nectin-4.

2. (a) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 13, or an amino acid sequence having at least 90%, at least 95%, or at least 99% identity thereto; and (b) the antibody or antigen-binding fragment of claim 1, comprising a VL region comprising the amino acid sequence set forth in SEQ ID NO: 14, or an amino acid sequence having at least 90%, at least 95%, or at least 99% identity thereto.

3. 3. The antibody or antigen-binding fragment of claim 1 or 2, which is a chimeric antibody, a multispecific antibody, a humanized antibody or an antigen-binding fragment thereof.

4. The antibody or antigen-binding fragment according to any one of claims 1 to 3, which is an antibody or antigen-binding fragment thereof of class IgG, class IgM, class IgA, or which is a single chain antibody or an antibody Fv fragment.

5. (a) (i) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 27; and (ii) a VL region comprising the amino acid sequence set forth in SEQ ID NO: 28; or (b) (i) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 41; and (ii) a VL region comprising the amino acid sequence set forth in SEQ ID NO: 42; or (c) (i) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 55; and (ii) a VL region comprising the amino acid sequence set forth in SEQ ID NO: 56; or (d) (i) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 69; and (ii) a VL region comprising the amino acid sequence set forth in SEQ ID NO: 70 or 103; or (e) (i) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 41; and (ii) a VL region comprising the amino acid sequence set forth in SEQ ID NO: 56; or (f) (i) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 41; and (ii) a VL region comprising the amino acid sequence set forth in SEQ ID NO: 70 or 103; or (g) (i) a VL region comprising the amino acid sequence set forth in SEQ ID NO: 55; and (ii) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 70 or 103; or (h) (i) a VH region comprising the amino acid sequence set forth in SEQ ID NO: 69; and (ii) a VL region comprising the amino acid sequence set forth in SEQ ID NO: 56 The antibody or antigen-binding fragment of any one of claims 1 to 4, comprising:

6. An antibody or antigen-binding fragment according to any one of claims 1 to 5 for use in medicine.

7. The antibody or antigen-binding fragment according to any one of claims 1 to 5 for use according to claim 6 in a method for preventing and / or treating cancer and / or inflammatory disorders.

8. The antibody or antigen-binding fragment of any one of claims 1 to 5 for use according to claim 6 or 7, wherein the cancer is associated with Nectin-4 overexpression.

9. The antibody or antigen-binding fragment according to any one of claims 1 to 5 for use according to any one of claims 6 to 8, wherein the cancer is urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer.

10. A nucleic acid encoding one or more of the antibodies of any one of claims 1 to 5, or at least one VL and / or one VH of any one of the antibodies of any one of claims 1 to 5.

11. A vector comprising the nucleic acid of claim 10.

12. A host cell comprising the vector of claim 11.

13. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.

14. The antibody or antigen-binding fragment of any one of claims 1 to 9, wherein the antibody is a chimeric antibody or an antigen-binding fragment thereof.

15. The antibody or antigen-binding fragment of any one of claims 1 to 9, wherein the antibody is a humanized antibody or an antigen-binding fragment thereof.

16. The antibody or antigen-binding fragment according to any one of claims 1 to 9, wherein the antibody is of subclass IgG1 or an antigen-binding fragment thereof.

17. The antibody or antigen-binding fragment according to any one of claims 1 to 9, wherein the antibody is of subclass IgG2 or an antigen-binding fragment thereof.

18. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, wherein the antibody is of subclass IgG3 or an antigen-binding fragment thereof.

19. The antibody or antigen-binding fragment according to any one of claims 1 to 9, wherein the antibody is of subclass IgG4 or an antigen-binding fragment thereof.

Citation Information

Patent Citations

  • Antibodies with specificity for Nectin-4 and uses thereof

    JP2018531913A

  • Antibodies specific to NECTIN-4 and uses thereof

    JP2020510432A